Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

Published:2021-11-01 Issue:11 Volume:6 Page:1298
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Docherty Kieran F.¹,Jhund Pardeep S.¹,Claggett Brian²,Ferreira João Pedro¹³,Bengtsson Olof⁴,Inzucchi Silvio E.⁵,Køber Lars⁶,Kosiborod Mikhail N.⁷⁸,Langkilde Anna Maria⁴,Martinez Felipe A.⁹,Ponikowski Piotr¹⁰,Sabatine Marc S.¹¹,Sjöstrand Mikaela⁴,Solomon Scott D.²,McMurray John J. V.¹,McMurray John J.V.¹²,DeMets David L.¹²,Inzucchi Silvio E¹²,Køber Lars¹²,Kosiborod Mikhail N.¹²,Langkilde Anna Maria¹²,Martinez Felipe A.¹²,Ponikowski Piotr¹²,Sabatine Marc S.¹²,Sjöstrand Mikaela¹²,Solomon Scott D.¹²,Diez Mirta¹²,Nicolau Jose Carlos¹²,Katova Tzvetana¹²,Howlett Jonathan¹²,O’Meara Eileen¹²,Verma Subodh¹²,Ge Junbo¹²,Belohlavek Jan¹²,Schou Morten¹²,Böhm Michael¹²,Merkely Bela¹²,Chopra Vijay¹²,Kitakaze Masahumi¹²,De Boer Rudolf¹²,Drożdż Jarosław¹²,Tereshchenko Sergey¹²,Dukát Andrej¹²,Ljungman Charlotta¹²,Chiang Chern-En¹²,Petrie Mark¹²,Anand Inder¹²,Desai Akshay¹²,Nguyễn Vinh Pham¹²,Sassone S¹²,Aizenberg D¹²,Talavera M¹²,Mercau G¹²,Martinez D¹²,Albisu J¹²,Hershson A¹²,García Durán R¹²,Hominal M¹²,Cluigt N¹²,Colombo Berra F¹²,Perna E¹²,Ahuad Guerrero R¹²,García Brasca D¹²,Zaidman C¹²,Majul C¹²,Taborda J¹²,Luquez H¹²,Sala J¹²,Sosa Liprandi A¹²,Cursack G¹²,Montaña O¹²,Fernandez A¹²,Najenson M¹²,Nani S¹²,Caruso G¹²,Fairman E¹²,Pereiro Gonzalez S¹²,Maia L¹²,Pereira A¹²,Rossi P¹²,Precoma D¹²,Neuenschwander F¹²,Reis G¹²,Guimaraes F¹²,Saraiva J¹²,Arantes F¹²,Hernandes M¹²,Borges J¹²,Paolino B¹²,Vasconcellos E¹²,Manenti E¹²,Pimentel P¹²,Leaes P¹²,Rassi S¹²,Dalcoquio T¹²,Katova T¹²,Avramov D¹²,Spasova N¹²,Raev D¹²,Chompalova B¹²,Milanova M¹²,Tokmakova M¹²,Runev N¹²,Mihov A¹²,Gogov A¹²,Dincheva A¹²,Iliev N¹²,Kolomanov B¹²,Ivanova Y¹²,Ilieva K¹²,Karageorgiev D¹²,Efremov I¹²,Botushanov N¹²,Vladeva S¹²,Constance C¹²,Vizel S¹²,Pandey A¹²,Phaneuf D¹²,Mehta S¹²,Rupka D¹²,Pesant Y¹²,Poirier P¹²,Chehayeb R¹²,Babapulle M¹²,O’Meara E¹²,Howlett J¹²,Yao L¹²,Mckelvie R¹²,Verma S¹²,Hartleib M¹²,Vijayaraghavan R¹²,Vyselaar J¹²,Azzari F¹²,Cha J¹²,Nasser-Sharif F¹²,Maung T.Z.¹²,Mansour S¹²,Khaykin Y¹²,Lee R¹²,Fong P¹²,Jiang H¹²,Li X¹²,Fu L¹²,Li Y¹²,Wang D¹²,Zhao Q¹²,Dong Y¹²,Zhou Y¹²,Lin X¹²,Dong J¹²,Zhang X¹²,Zheng Z¹²,Huang W¹²,Gu Y¹²,Liu J¹²,Guo X¹²,Wu L¹²,Tang Q¹²,Peng D¹²,Dong W¹²,Liang Y¹²,Li Z¹²,Wang Z¹²,Han B¹²,Wu C¹²,Belohlavek J¹²,Slaby J¹²,Spinar J¹²,Hajek P¹²,Busak L¹²,Carda J¹²,Spinarova L¹²,Malek I¹²,Skopek J¹²,Kuchar R¹²,Krcova E¹²,Mayer Jr O¹²,Kucera D¹²,Schou M¹²,Køber L¹²,Egstrup K¹²,Hove J¹²,Gislason G¹²,Videbæk L¹²,Böhm M¹²,Nischik R¹²,Toursarkissian N¹²,Appel K¹²,Schmidt E¹²,Weigmann I¹²,Kellerer M¹²,Al-Zoebi A¹²,Stephan U¹²,Wilke A¹²,Genth-Zotz S¹²,Simonis G¹²,Tschöpe D¹²,Costard-Jäckle A¹²,Merkely B¹²,Andrássy P¹²,Noori E¹²,Járai Z¹²,Poór F¹²,Király C¹²,Czigány A¹²,Nagy L¹²,Motyovszki Á¹²,Masszi G¹²,Mehta V¹²,Chopra V¹²,Naik A¹²,Gadkari M¹²,Sawant R¹²,Mahapekar M¹²,Karna S¹²,Deshpande M¹²,Bhargava V¹²,Kothiwale V¹²,Menon J¹²,Sinha D¹²,Sinha S¹²,Kokane H¹²,Udgire P¹²,Sandhu M¹²,Suzuki M¹²,Nishino M¹²,Kiyosue A¹²,Sumii K¹²,Suzuki S¹²,Noguchi Y¹²,Tanaka S¹²,Takase H¹²,Mohri M¹²,Higashiue S¹²,Fujimoto N¹²,Iseki H¹²,Kuramochi T¹²,Shibasaki T¹²,Tsutsui H¹²,Takagi Y¹²,Katayama Y¹²,Takeyasu N¹²,Anzai T¹²,Nagashima H¹²,Kimura A¹²,Kakuta T¹²,Hashimoto T¹²,Sugino H¹²,Saito K¹²,Hiroi S¹²,Kamiya H¹²,Fukui K¹²,Matsuoka S¹²,Moritani K¹²,Tomobuchi Y¹²,Hata Y¹²,Kawamura R¹²,Hattori E¹²,Fujimoto K¹²,Takahashi N¹²,Takahashi W¹²,Kadokami T¹²,Ueno H¹²,Uchikawa S¹²,Shinozaki T¹²,Onishi Y¹²,Komiyama N¹²,Inoue S¹²,Momiyama Y¹²,Ueda Y¹²,Komura Y¹²,Arakawa T¹²,Meno H¹²,Higuchi M¹²,Hayashi Y¹²,Seki K¹²,Fujii K¹²,Harada K¹²,Wada A¹²,Kasai T¹²,Kuwahara K¹²,Yasaka Y¹²,Uchida I¹²,Okumura Y¹²,Hisamatsu Y¹²,Nunohiro T¹²,Tsukahara K¹²,Hirohata A¹²,Asakura M¹²,De Boer R¹²,Bellersen L¹²,Swart H¹²,Groenemeijer B¹²,Zoet Nugteren S¹²,De Nooijer C¹²,Nierop P¹²,Robles De Medina R¹²,Van Eck J¹²,Van Hessen M¹²,Drożdż J¹²,Miękus P¹²,Ściborski R¹²,Mikłaszewicz B¹²,Sudnik W¹²,Mariankowski R¹²,Witek R¹²,Drelich G¹²,MirekBryniarska E¹²,Szynal S¹²,Pawłowicz L¹²,Lampart J¹²,Korzeniak R¹²,Prokopczuk J¹²,Boldueva S¹²,Didenko Y¹²,Dzhaiani N¹²,Ermoshkina L¹²,Kostenko V¹²,Vishneva E¹²,Koziolova N¹²,Tereschenko S¹²,Pevzner D¹²,Krylova L¹²,Chernyavsky A¹²,Kazakov A¹²,Aksentiev S¹²,Nilk R¹²,Paltsman Z¹²,Galyavich A¹²,Maltcev A¹²,Kopylov P¹²,Ezhov A¹²,Shilko J¹²,Antalik L¹²,Bugan V¹²,Fulop P¹²,Jamriskova L¹²,Kollarova D¹²,Macek V¹²,Slovenska M¹²,Tomasova L¹²,Vinanska D¹²,Smik R¹²,Selecky J¹²,Majercak I¹²,Olexa P¹²,Ljungman C¹²,Hedman A¹²,Lindholm C¹²,Lindmark K¹²,Mooe T¹²,Chiang C¹²,Lin L¹²,Liu M¹²,Chang K¹²,Hsia C¹²,Shih J¹²,Liu P¹²,Lin T¹²,Chang H¹²,Huang J¹²,Hsieh I¹²,Tseng W¹²,Petrie M¹²,Gardner R¹²,Clark A¹²,Japp A¹²,Jhund P¹²,Lang C¹²,Leslie S¹²,Murphy C¹²,Petrie C¹²,Walsh J¹²,Arif A¹²,Avino D¹²,Banerjee S¹²,Kanwar M¹²,Berk M¹²,Brown C¹²,Ince Jr C¹²,Lewis T¹²,Nikfarjam A¹²,Patel J¹²,Ramanathan K¹²,Schabauer A¹²,Greene T¹²,Shah K¹²,Sotolongo R¹²,Viera A¹²,Akinboboye O¹²,Arouni A¹²,Bertolet B¹²,Chandra L¹²,Cimato T¹²,Deleon S¹²,Bennett M¹²,Franchi F¹²,Hamroff G¹²,Hotchkiss D¹²,Jardula M¹²,Javier J¹²,Kazemi N¹²,Kostis J¹²,Lash J¹²,Levinson L¹²,Lieber I¹²,Lo E¹²,Mahal S¹²,Manshadi R¹²,Mody F¹²,Paraschos A¹²,Pursley M¹²,Hickey G¹²,Londono J¹²,Singal D¹²,Srivastava S¹²,Teel J¹²,Castriz J¹²,Kantaros L¹²,Venugopal C¹²,Staniloae C¹²,Gupta D¹²,Syed F¹²,Zacharias M¹²,Jaffrani N¹²,Wakefield P¹²,Nassif M¹²,Haddad T¹²,Iskander S¹²,Lewis G¹²,Al-Joundi B¹²,French W¹²,Ogunniyi M¹²,Emani S¹²,Weiss S¹²,Cheng R¹²,Florea V¹²,Joseph S¹²,Lederman S¹²,Izzo J¹²,Bernstein M¹²,Fruehling E¹²,Foley B¹²,Younis L¹²,Song D¹²,Pham V¹²,Nguyen H¹²,Do H¹²,Truong B¹²,Nguyen T¹²,Ho D¹²,

Affiliation:

1. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

2. Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts

3. National Institute of Health and Medical Research, Center for Clinical Multidisciplinary Research 1433, INSERM U1116, Nancy, France

4. AstraZeneca R&D, Gothenburg, Sweden

5. Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut

6. Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

7. Saint Luke's Mid America Heart Institute and University of Missouri–Kansas City

8. The George Institute for Global Health, University of New South Wales, Sydney, Australia

9. Universidad Nacional de Córdoba, Córdoba, Argentina

10. Center for Heart Diseases, Wroclaw Medical University, Wroclaw, Poland

11. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts

12. for the DAPA-HF Investigators and Committees

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2782405/jamacardiology_docherty_2021_oi_210049_1635348697.6498.pdf

Reference22 articles.

1. Dapagliflozin in patients with heart failure and reduced ejection fraction.;McMurray;N Engl J Med,2019

2. Cardiovascular and renal outcomes with empagliflozin in heart failure.;Packer;N Engl J Med,2020

3. Limitations of hazard ratios in clinical trials.;Stensrud;Eur Heart J,2019

4. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.;Uno;J Clin Oncol,2014

5. On the restricted mean survival time curve in survival analysis.;Zhao;Biometrics,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin;Journal of Clinical Medicine;2023-10-27

2. Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice;Diabetes mellitus;2023-07-07

3. Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events;ESC Heart Failure;2023-03-26

4. Dapagliflozin attenuates residual cardiac remodeling after surgical ventricular reconstruction in mice with an enlarged heart after myocardial infarction;Biomedicine & Pharmacotherapy;2022-12

5. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure;Journal of the American College of Cardiology;2022-11